These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 34391082)

  • 1. Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration.
    Fakhri S; Iranpanah A; Gravandi MM; Moradi SZ; Ranjbari M; Majnooni MB; Echeverría J; Qi Y; Wang M; Liao P; Farzaei MH; Xiao J
    Phytomedicine; 2021 Oct; 91():153664. PubMed ID: 34391082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pivotal role of JAK/STAT and IRS/PI3K signaling pathways in neurodegenerative diseases: Mechanistic approaches to polyphenols and alkaloids.
    Kooshki L; Zarneshan SN; Fakhri S; Moradi SZ; Echeverria J
    Phytomedicine; 2023 Apr; 112():154686. PubMed ID: 36804755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration.
    Heras-Sandoval D; Pérez-Rojas JM; Hernández-Damián J; Pedraza-Chaverri J
    Cell Signal; 2014 Dec; 26(12):2694-701. PubMed ID: 25173700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.
    Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A
    Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Abnormal PI3K/AKT/mTOR Signaling in Intracerebral Hemorrhage: A Systematic Review on Potential Drug Targets and Influences of Signaling Modulators on Other Neurological Disorders.
    Jadaun KS; Sharma A; Siddiqui EM; Mehan S
    Curr Rev Clin Exp Pharmacol; 2022; 17(3):174-191. PubMed ID: 34455956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds.
    Roy T; Boateng ST; Uddin MB; Banang-Mbeumi S; Yadav RK; Bock CR; Folahan JT; Siwe-Noundou X; Walker AL; King JA; Buerger C; Huang S; Chamcheu JC
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting new strategies in combating head and neck carcinoma: A comprehensive review on phytochemical approaches passing through PI3K/Akt/mTOR signaling pathway.
    Iranpanah A; Majnooni MB; Biganeh H; Amirian R; Rastegari-Pouyani M; Filosa R; Cheang WS; Fakhri S; Khan H
    Phytother Res; 2024 Jul; 38(7):3736-3762. PubMed ID: 38776136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
    Narayanankutty A
    Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
    Narayanankutty A
    Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling.
    El-Sayed RM; Abdelaziz AM; Zaki HF; Abdel Rasheed NO
    Int Immunopharmacol; 2023 Apr; 117():109986. PubMed ID: 37012873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.
    Chamcheu JC; Roy T; Uddin MB; Banang-Mbeumi S; Chamcheu RN; Walker AL; Liu YY; Huang S
    Cells; 2019 Jul; 8(8):. PubMed ID: 31370278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PI3K/Akt/mTOR signaling by natural products.
    Huang S
    Anticancer Agents Med Chem; 2013 Sep; 13(7):967-70. PubMed ID: 23272914
    [No Abstract]   [Full Text] [Related]  

  • 14. S6K Promotes Dopaminergic Neuronal Differentiation Through PI3K/Akt/mTOR-Dependent Signaling Pathways in Human Neural Stem Cells.
    Lee JE; Lim MS; Park JH; Park CH; Koh HC
    Mol Neurobiol; 2016 Aug; 53(6):3771-3782. PubMed ID: 26143260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents.
    Sun H; Wang Z; Yakisich JS
    Anticancer Agents Med Chem; 2013 Sep; 13(7):1048-56. PubMed ID: 23293890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMGB1/PI3K/Akt/mTOR Signaling Participates in the Pathological Process of Acute Lung Injury by Regulating the Maturation and Function of Dendritic Cells.
    Li R; Zou X; Huang H; Yu Y; Zhang H; Liu P; Pan S; Ouyang Y; Shang Y
    Front Immunol; 2020; 11():1104. PubMed ID: 32636835
    [No Abstract]   [Full Text] [Related]  

  • 17. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
    Narayanankutty A
    Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy protects against PI3K/Akt/mTOR-mediated apoptosis of spinal cord neurons after mechanical injury.
    Wang Z; Zhou L; Zheng X; Chen G; Pan R; Li J; Liu W
    Neurosci Lett; 2017 Aug; 656():158-164. PubMed ID: 28739349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy.
    Xu Z; Han X; Ou D; Liu T; Li Z; Jiang G; Liu J; Zhang J
    Appl Microbiol Biotechnol; 2020 Jan; 104(2):575-587. PubMed ID: 31832711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
    Singh P; Kumar V; Gupta SK; Kumari G; Verma M
    Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.